Free public records show Bluejay Diagnostics, Inc. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Bluejay Diagnostics, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1704287. Retrieved 13 Nov 2026.
2 active studies led by Bluejay Diagnostics, Inc., of 7 in all
Source: ClinicalTrials.gov, Studies with Bluejay Diagnostics, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1704287.
Studies Bluejay Diagnostics, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Bluejay Diagnostics, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Bluejay Diagnostics, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Bluejay Diagnostics, Inc. is in.
Stories on the topics Bluejay Diagnostics, Inc. works in.
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
ReadSearch all reports for Bluejay Diagnostics, Inc. All companies